{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:39:57Z","timestamp":1760297997351},"reference-count":29,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2008,7,21]],"date-time":"2008-07-21T00:00:00Z","timestamp":1216598400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2008,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Fludarabine plus cyclophosphamide (FC) at conventional doses is an effective treatment for chronic lymphocytic leukaemia (CLL). However, FC at standard doses may give hematological and non\u2010hematological toxicity, predominantly in the elderly. Intravenous or oral low\u2010dose FC regimens remain highly effective in elderly patients with Low\u2010Grade Lymphomas other than CLL and are well tolerated. We tested efficacy and toxicity of oral FC at reduced doses in 26 elderly patients (median 71 years) with previously untreated (UT\u2010CLL, <jats:italic>n<\/jats:italic>\u2009=\u200914) or relapsed\/refractory CLL (R\u2010CLL, <jats:italic>n<\/jats:italic>\u2009=\u200912), unfit for conventional treatments. Twentyfour\u2010of\u201026 (92%) patients (14\/14, 100% UT\u2010CLL; 10\/12, 83.5% R\u2010CLL) obtained a response, with 12\/26 (46%) complete responses (9\/14, 64.2% in UT\u2010CLL; 3\/12, 25% in R\u2010CLL). Non\u2010hematological toxicity was mild and myelosuppression was documented in 8\/26 (31%) patients (4\/14, 28% UT\u2010CLL; 4\/12, 33% R\u2010CLL). With a median follow\u2010up of 24 months, median event\u2010free survival was 48 months with no differences between UT\u2010CLL and R\u2010CLL and all responders were alive. Low\u2010dose oral FC treatment showed good efficacy in both untreated and refractory\/relapsed CLL. The treatment is useful in elderly patients who cannot benefit of more aggressive schedules and is easy to administer on an outpatient basis. Copyright \u00a9 2008 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/hon.868","type":"journal-article","created":{"date-parts":[[2008,7,21]],"date-time":"2008-07-21T07:37:50Z","timestamp":1216625870000},"page":"247-251","source":"Crossref","is-referenced-by-count":29,"title":["Low\u2010dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia"],"prefix":"10.1002","volume":"26","author":[{"given":"Francesco","family":"Forconi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Fabbri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariapia","family":"Lenoci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Sozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Gozzetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maristella","family":"Tassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donatella","family":"Raspadori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Lauria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,7,21]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa023143"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012283432602"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2007.02.001"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.6.1848"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040857"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61125-8"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2395"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.0762"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.8.2836.420k35_2836_2843"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.5.1414"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06382.x"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1080\/1042819031000110991"},{"key":"e_1_2_1_14_2","first-page":"716","article-title":"Favorable impact of low\u2010dose fludarabine plus epirubicin and cyclophosphamide regimen (FLEC) as treatment for low\u2010grade non\u2010Hodgkin's lymphomas","volume":"84","author":"Bocchia M","year":"1999","journal-title":"Haematologica"},{"key":"e_1_2_1_15_2","first-page":"1268","article-title":"Low\u2010dose fludarabine and cyclophosphamide in elderly patients with B\u2010cell chronic lymphocytic leukemia refractory to conventional therapy","volume":"85","author":"Marotta G","year":"2000","journal-title":"Haematologica"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06746.x"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1968.tb02103.x"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.4.1174"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-109488"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.4451"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-093906"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20234"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200563"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01212.x"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.22.4252"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200363210-00004"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.9313"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.051"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.516"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.868","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.868","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T12:04:15Z","timestamp":1699963455000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,21]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["10.1002\/hon.868"],"URL":"https:\/\/doi.org\/10.1002\/hon.868","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,21]]}}}